Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.
Journal of immunology (Baltimore, Md. : 1950) Nov, 2014 | Pubmed ID: 25281717